Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The present 24-week, prospective, open-label, randomized, multicenter, parallel group trial
is carried to investigate and evaluate the efficacy and safety of Liraglutide in combination
with prandial insulin therapy vs insulin glargine in combination with prandial insulin
therapy in overweight / obese patients with uncontrolled type 2 diabetes.
Phase:
Phase 4
Details
Lead Sponsor:
The First Affiliated Hospital of Xiamen University